| Symbol | SER |
|---|---|
| Name | SERINA THERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 601 GENOME WAY, HUNTSVILLE, AL 35806 |
| Telephone | (256) 327-9630 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001708599 |
| Description | None |
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Read more(30% Negative) SERINA THERAPEUTICS, INC. (SER) Reports Q3 2026 Financial Results
Read moreNew Form S-8 - Serina Therapeutics, Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001493152-26-037846 <b>Size:</b> 213 KB
Read moreSerina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Read moreDirector Simon Farrell 🟢 acquired 30.5K shares (1 derivative) of Serina Therapeutics, Inc. (SER) at $2.17 Transaction Date: Jul 22, 2026 | Filing ID: 000006
Read more(99% Neutral) SERINA THERAPEUTICS, INC. (SER) Announces Executive Departure
Read moreNew Form 3 - Serina Therapeutics, Inc. <b>Filed:</b> 2026-07-23 <b>AccNo:</b> 0001965585-26-000004 <b>Size:</b> 7 KB
Read moreSerina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Read more(99% Neutral) SERINA THERAPEUTICS, INC. (SER) Provides Update on expertise for commercial strategy
Read more